Sun G, Wang Z, Han Q, Liu B, Chen H. Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case...
Toggle Sidebar Find Previous Next Presentation ModeOpenPrintDownloadCurrent View Tools Zoom Out Zoom In Automatic ZoomActual SizePage FitPage Width50%75%100%125%150%200%300%400%
The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, MSS-type and KRAS-mutated metastatic colorectal cancer although its application to the general public still needs to be validated in clinical trials.Lij...
3. Zhu G, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021 Nov 6;20(1):143. 4. Fakih M, et al. Real-World Study of Characteristics and Treatm...
The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific
providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance. Here, we review the metabolic reprogramming of glucose, glutamine, and lipids ...
(G12C) mutated cancer cell lines. However, the safety evaluation system, pharmacodynamic studies, and dose selection of the proteolysis-targeting chimeras (PROTACs) technique need to be improved. The covalent nature of LC-2 may limit its potency because it fails to participate in catalytic rounds...
patients, the expression of PD-L1 in tumours in the TP53/KRAS comutation group was increased, and the proportion of CD8 + T cells in TME was higher, which was consistent with the clinical benefit of TP53, KRAS or TP53/KRAS-mutated cancer patients after treatment with PD-1 inhibitors113. ...
These findings indicate that cRGD-BCP-siKRAS could hold promise as a treatment for KRAS G12D-mutated pancreatic cancer. Perepelyuk et al. reported the in vivo therapeutic efficacy of siRNA targeting KRAS G12S mutation in non-small-cell lung cancer (NSCLC) [92]. In this study, authors ...
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activati